Public procurement notice: Contract Notice
Published: 2018-09-22
Buyer: The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 130023407 GBP
Submission deadline: 2018-10-24
Award criteria: The most economic tender

Technical requirements: The Framework Agreement is for the supply of adalimumab 20 mg, 40 mg, 80 mg presentations to health boards across NHS Scotland.
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
This Framework Agreement is for the supply of adalimumab presentations to NHS Scotland. This will require supply of the Goods direct to hospitals and nominated home delivery supplier(s) as directed by the Authority.
The Framework Agreement includes the provision of Goods only and Goods with manufacturer funded homecare.
Each product line will be treated as an individual Lot and will be awarded on a line by line basis. It is envisaged that each Lot will be awarded as an unranked multi supplier Framework to a maximum of six (6) Framework Participants.
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.
(a) potential framework participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Goods for the commencement of the Framework Agreement.
(b) potential framework participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) all tendered goods must comply with the MHRA best practice guidance on labeling and packaging and the National Patient Safety Agency ("NPSA") Guidelines on packaging and labeling on pack design.
(a) Confirmation that a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Goods will be in place for the start date of the Framework Agreement should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.
(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under Technical and Professional ability: Quality Assurance Schemes.
(c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best practice guidance on labeling and Packaging and the National Patient Safety Agency ("NPSA") guidelines on packaging and labeling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.
The estimated values referred to in Sections II.I.5 and II.2.6 cover the initial twelve (12) month duration and the maximum twenty four (24) months extension period.
The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 11954. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343

Eligibility requirements: Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.

Award value: 130023407